Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL IMMUNOLOGY
Volume 41, Issue 7, Pages 1425-1442
Publisher
Springer Science and Business Media LLC
Online
2021-06-08
DOI
10.1007/s10875-021-01068-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
- (2021) Romina Libster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
- (2021) Tyler N. Starr et al. SCIENCE
- Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
- (2021) Viviane C Veiga et al. BMJ-British Medical Journal
- Emerging B-Cell Therapies in Systemic Lupus Erythematosus
- (2021) Ayse Bag-Ozbek et al. Therapeutics and Clinical Risk Management
- Efficacy of convalescent plasma therapy for COVID ‐19: A systematic review and meta‐analysis
- (2021) Charan T. R. Vegivinti et al. JOURNAL OF CLINICAL APHERESIS
- Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup
- (2021) Eric J. Rubin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study
- (2021) Robert Challen et al. BMJ-British Medical Journal
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway
- (2021) Isabelle Meyts et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients
- (2021) Rutger Koning et al. INTENSIVE CARE MEDICINE
- Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
- (2021) Sara E. Vazquez et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
- (2021) Jesús Troya et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
- (2021) Prasanna Jagannathan et al. Nature Communications
- Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: ‘Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia’ by Guilpain et al
- (2020) Sara Monti et al. ANNALS OF THE RHEUMATIC DISEASES
- Plasmapheresis treatment in COVID-19–related autoimmune meningoencephalitis: Case series
- (2020) Lerzan Dogan et al. BRAIN BEHAVIOR AND IMMUNITY
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19
- (2020) Jie Ma et al. CLINICAL IMMUNOLOGY
- Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection
- (2020) Hua Shi et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
- (2020) Isabella Quinti et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Type I IFN immunoprofiling in COVID-19 patients
- (2020) Sophie Trouillet-Assant et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Deployment of convalescent plasma for the prevention and treatment of COVID-19
- (2020) Evan M. Bloch et al. JOURNAL OF CLINICAL INVESTIGATION
- Translating JAKs to Jakinibs
- (2020) Massimo Gadina et al. JOURNAL OF IMMUNOLOGY
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- (2020) Kelvin Kai-Wang To et al. LANCET INFECTIOUS DISEASES
- Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
- (2020) T. Klopfenstein et al. MEDECINE ET MALADIES INFECTIEUSES
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover
- (2020) Annarosa Soresina et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- Get rid of the bad first: Therapeutic plasma exchange with convalescent plasma for severe COVID-19
- (2020) Selman Kesici et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Convalescent plasma to treat coronavirus disease 2019 (COVID‐19): considerations for clinical trial design
- (2020) Paul Barone et al. TRANSFUSION
- Recovery of severely ill COVID-19 patients by intravenous immunoglobulin (IVIG) treatment: A case series
- (2020) Negar Mohtadi et al. VIROLOGY
- Mild course of Coronavirus disease 2019 and spontaneous severe acute respiratory syndrome coronavirus 2 clearance in a patient with depleted peripheral blood B‐cells due to treatment with rituximab
- (2020) Benedict Fallet et al. Arthritis & Rheumatology
- Interferon-α2b Treatment for COVID-19
- (2020) Qiong Zhou et al. Frontiers in Immunology
- High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019
- (2020) Wei Cao et al. Open Forum Infectious Diseases
- Effectiveness of intravenous immunoglobulin for children with severe COVID-19: a rapid review
- (2020) Jingyi Zhang et al. Annals of Translational Medicine
- Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies
- (2020) Carlos Sanchez-Piedra et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al
- (2020) Hendrik Schulze-Koops et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial
- (2020) Effat Davoudi-Monfared et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antiviral activities of type I interferons to SARS-CoV-2 infection
- (2020) Emily Mantlo et al. ANTIVIRAL RESEARCH
- Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients
- (2020) Nan Wang et al. Cell Host & Microbe
- Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-IFN-γ autoantibodies
- (2020) Sebastian Ochoa et al. CLINICAL INFECTIOUS DISEASES
- Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
- (2020) Denise J. Wooding et al. CLINICAL MICROBIOLOGY AND INFECTION
- Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
- (2020) Farzaneh Dastan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b
- (2020) Sun In Hong et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- An Old Cytokine Against a New Virus?
- (2020) Sandra Pellegrini et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Application of plasma exchange in association with higher dose CVVH in Cytokine Storm Complicating COVID-19
- (2020) Jui-Hsiang Lin et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Type I and Type III IFN Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures
- (2020) Abigail Vanderheiden et al. JOURNAL OF VIROLOGY
- A perspective on potential antibody-dependent enhancement of SARS-CoV-2
- (2020) Ann M. Arvin et al. NATURE
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
- (2020) Jérôme Hadjadj et al. SCIENCE
- Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
- (2020) Jack Major et al. SCIENCE
- Type III interferons disrupt the lung epithelial barrier upon viral recognition
- (2020) Achille Broggi et al. SCIENCE
- Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab
- (2020) Jan Leipe et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- A pilot study of therapeutic plasma exchange for serious SARS CoV-2 disease (COVID-19): A structured summary of a randomized controlled trial study protocol
- (2020) Fahad Faqihi et al. Trials
- High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects
- (2020) Xiaosheng Liu et al. Frontiers in Immunology
- Therapeutic Plasma Exchange: A potential Management Strategy for Critically Ill COVID-19 Patients
- (2020) Seena Tabibi et al. JOURNAL OF INTENSIVE CARE MEDICINE
- Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
- (2020) Mark Roschewski et al. Science Immunology
- The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
- (2020) Naser Gharebaghi et al. BMC INFECTIOUS DISEASES
- Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma
- (2020) Hajime Yasuda et al. Clinical Lymphoma Myeloma & Leukemia
- Convalescent plasma treatment for COVID‐19: Tempering expectations with the influenza experience
- (2020) Kanta Subbarao et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
- (2020) et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronavirus disease 2019 in patients with inborn errors of immunity: An international study
- (2020) Isabelle Meyts et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
- (2020) Hans-Hartmut Peter et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
- (2020) Kenneth H. Dinnon et al. NATURE
- Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome
- (2020) Yaseen M. Arabi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study
- (2020) Jesús Loarce-Martos et al. RHEUMATOLOGY INTERNATIONAL
- Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease
- (2020) Chia Siang Kow et al. RHEUMATOLOGY INTERNATIONAL
- Susceptibility to severe COVID-19
- (2020) David B. Beck et al. SCIENCE
- An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial
- (2020) Ilad Alavi Darazam et al. Trials
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
- (2020) Carlo Salvarani et al. JAMA Internal Medicine
- Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
- (2020) Nicky Dunn et al. Frontiers in Immunology
- Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020
- (2020) Sapna Bamrah Morris et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab
- (2020) Igor Kos et al. Frontiers in Oncology
- Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial
- (2020) Payam Tabarsi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
- (2020) Faryal Khamis et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- (2020) Carlos Salama et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
- (2020) Ventura A. Simonovich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon β-1a (IFNβ-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial
- (2020) Emanuele Bosi et al. Trials
- Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience
- (2020) Aurélien Mary et al. Frontiers in Pharmacology
- Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis
- (2020) Dominica Ratuszny et al. Frontiers in Neurology
- Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2020) Phillip D Monk et al. Lancet Respiratory Medicine
- Disseminated non-tuberculous mycobacterial infection associated with acquired immunodeficiency due to anti-IFN-γ autoantibodies
- (2019) Arvind Yerramilli et al. Open Forum Infectious Diseases
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
- (2019) Anand Padmanabhan et al. JOURNAL OF CLINICAL APHERESIS
- Successful treatment with daratumumab for post‐HSCT refractory hemolytic anemia
- (2019) Ehud Even‐Or et al. PEDIATRIC BLOOD & CANCER
- Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
- (2018) Aruna Aruna et al. MEDICAL SCIENCE MONITOR
- Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies
- (2018) Kim A. Papp et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Persistent Mycobacterium abscessus infection secondary to interferon-γ autoantibodies
- (2016) Roshni Naik et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- DisseminatedTalaromyces marneffeiandMycobacterium abscessusin a Patient With Anti-Interferon-γ Autoantibodies
- (2016) Nattapol Pruetpongpun et al. Open Forum Infectious Diseases
- Prediction of a sustained viral response in chronic hepatitis C patients who undergo induction therapy with double filtration plasmapheresis plus interferon-β/ribavirin
- (2015) TORU ISHIKAWA et al. Experimental and Therapeutic Medicine
- Interferons: Success in anti-viral immunotherapy
- (2014) Fan-ching Lin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Evaluation of Plasma Exchange and Continuous Veno-Venous Hemofiltration for the Treatment of Severe Avian Influenza A (H7N9): A Cohort Study
- (2014) Xiaoli Liu et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Rituximab as Successful Adjunct Treatment in a Patient With Disseminated Nontuberculous Mycobacterial Infection Due to Acquired Anti-Interferon- Autoantibody
- (2013) C. A. Czaja et al. CLINICAL INFECTIOUS DISEASES
- Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis
- (2013) Silvia N. Tenembaum et al. JOURNAL OF CHILD NEUROLOGY
- Interferon- and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
- (2013) B. J. Hart et al. JOURNAL OF GENERAL VIROLOGY
- Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
- (2013) Tomas Kalincik et al. PLoS One
- Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia
- (2013) Stefania Crotta et al. PLoS Pathogens
- Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid
- (2012) Bernard R. Lauwerys et al. ARTHRITIS AND RHEUMATISM
- Anti-CD20 (rituximab) therapy for anti-IFN- autoantibody-associated nontuberculous mycobacterial infection
- (2012) S. K. Browne et al. BLOOD
- Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent
- (2012) Philippa Hillyer et al. IMMUNOLOGY AND CELL BIOLOGY
- Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases
- (2012) Erwin W. Gelfand NEW ENGLAND JOURNAL OF MEDICINE
- Adverse effects of plasma transfusion
- (2012) Suchitra Pandey et al. TRANSFUSION
- Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C
- (2011) Mark S. Sulkowski et al. Nature Reviews Gastroenterology & Hepatology
- Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C
- (2010) Alessio Aghemo et al. Nature Reviews Gastroenterology & Hepatology
- Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza A—An associated respiratory failure and hemodynamic shock
- (2010) Pritesh Patel et al. Pediatric Critical Care Medicine
- Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome
- (2008) Pieter A van Doorn et al. LANCET NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now